Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by SELLAS Life Sciences Group, Inc. on June 8, 2022. The filing details the voting results for three proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
At the Annual Meeting, 11,383,855 shares (approximately 55.43% of outstanding shares) were present or represented by proxy. The results for the three proposals were as follows:
- Proposal 1 (Director Election): Stockholders re-elected Class III directors Angelos M. Stergiou and John Varian.
- Angelos M. Stergiou: 5,020,918 For; 857,185 Withheld.
- John Varian: 4,678,719 For; 1,199,384 Withheld.
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of Moss Adams LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Votes: 10,499,410 For; 765,119 Against; 119,326 Abstain.
- Proposal 3 (Say-on-Pay): Stockholders approved the non-binding advisory resolution on executive compensation.
- Votes: 4,224,292 For; 1,575,977 Against; 77,834 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the tenure of the newly re-elected directors (Angelos M. Stergiou and John Varian) through the 2025 Annual Meeting.
- Confirm the engagement of Moss Adams LLP for the fiscal year ending December 31, 2022.
- Note the significant number of broker non-votes (5,505,752) on the executive compensation proposal, which may indicate institutional investor abstention or lack of voting instructions.